Assessment of hemostasis in platelet transfusion clinical trials with differential follow-up

摘要

In the recent publication, 'Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system', Vamvakas limits the analysis to bleeding complications in the randomized clinical trials described in peer-reviewed scientific publications [1]. These bleeding complications are reported as proportions, for example, number of patients in the treatment group experiencing a Grade 2 bleeding event divided by the number of patients in the treatment group. However, an underlying assumption in using proportions to quantify bleeding complications is that patients are observed for exactly the same period of time.